Cargando…

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab

PURPOSE: To report the effects of aflibercept on eyes with large retinal pigment epithelial detachment (PED) associted with polypoidal choroidal vasculopathy (PCV). METHODS: We reviewed the medical records of patients with PEDs associated with PCV that were treated with aflibercept after intravitrea...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Mariko, Nishi, Tomo, Hasegawa, Taiji, Ogata, Nahoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935506/
https://www.ncbi.nlm.nih.gov/pubmed/24591809
http://dx.doi.org/10.2147/OPTH.S56539
_version_ 1782305197516652544
author Yamashita, Mariko
Nishi, Tomo
Hasegawa, Taiji
Ogata, Nahoko
author_facet Yamashita, Mariko
Nishi, Tomo
Hasegawa, Taiji
Ogata, Nahoko
author_sort Yamashita, Mariko
collection PubMed
description PURPOSE: To report the effects of aflibercept on eyes with large retinal pigment epithelial detachment (PED) associted with polypoidal choroidal vasculopathy (PCV). METHODS: We reviewed the medical records of patients with PEDs associated with PCV that were treated with aflibercept after intravitreal ranibizumab had failed. RESULTS: Three eyes of patients aged 72, 79, and 80 years were studied. Reflective material was seen in the PED along the outer surface of the retinal pigment epithelium (RPE) by spectral-domain optical coherence tomography (SD-OCT). A complete resolution of the serous PEDs was found after two aflibercept injections; however, all eyes had a fibrovascular PED. In addition, one eye developed a retinal hemorrhage and a recurrent PED just after the third injection of aflibercept. The visual acuity in this eye decreased from 10/20 to 2/20. CONCLUSION: The reflective material below the outer surface of the RPE in serous PED suggests the presence of neovascularization. Intravitreal aflibercept could be considered for large PEDs in eyes with PCV but should be carefully applied.
format Online
Article
Text
id pubmed-3935506
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-39355062014-03-03 Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab Yamashita, Mariko Nishi, Tomo Hasegawa, Taiji Ogata, Nahoko Clin Ophthalmol Case Report PURPOSE: To report the effects of aflibercept on eyes with large retinal pigment epithelial detachment (PED) associted with polypoidal choroidal vasculopathy (PCV). METHODS: We reviewed the medical records of patients with PEDs associated with PCV that were treated with aflibercept after intravitreal ranibizumab had failed. RESULTS: Three eyes of patients aged 72, 79, and 80 years were studied. Reflective material was seen in the PED along the outer surface of the retinal pigment epithelium (RPE) by spectral-domain optical coherence tomography (SD-OCT). A complete resolution of the serous PEDs was found after two aflibercept injections; however, all eyes had a fibrovascular PED. In addition, one eye developed a retinal hemorrhage and a recurrent PED just after the third injection of aflibercept. The visual acuity in this eye decreased from 10/20 to 2/20. CONCLUSION: The reflective material below the outer surface of the RPE in serous PED suggests the presence of neovascularization. Intravitreal aflibercept could be considered for large PEDs in eyes with PCV but should be carefully applied. Dove Medical Press 2014-03-02 /pmc/articles/PMC3935506/ /pubmed/24591809 http://dx.doi.org/10.2147/OPTH.S56539 Text en © 2014 Yamashita et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Yamashita, Mariko
Nishi, Tomo
Hasegawa, Taiji
Ogata, Nahoko
Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
title Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
title_full Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
title_fullStr Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
title_full_unstemmed Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
title_short Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
title_sort response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935506/
https://www.ncbi.nlm.nih.gov/pubmed/24591809
http://dx.doi.org/10.2147/OPTH.S56539
work_keys_str_mv AT yamashitamariko responseofserousretinalpigmentepithelialdetachmentstointravitrealafliberceptinpolypoidalchoroidalvasculopathyrefractorytoranibizumab
AT nishitomo responseofserousretinalpigmentepithelialdetachmentstointravitrealafliberceptinpolypoidalchoroidalvasculopathyrefractorytoranibizumab
AT hasegawataiji responseofserousretinalpigmentepithelialdetachmentstointravitrealafliberceptinpolypoidalchoroidalvasculopathyrefractorytoranibizumab
AT ogatanahoko responseofserousretinalpigmentepithelialdetachmentstointravitrealafliberceptinpolypoidalchoroidalvasculopathyrefractorytoranibizumab